Myriamed

Executive Summary

Myriamed, based in Munich, Germany, is a preclinical-stage company leveraging proprietary human cell and engineered tissue models to enhance drug development. Founded in 2020, its platform enables drug developers to define safer and more effective doses for first-in-human studies, potentially reducing costly late-stage failures. By integrating advanced in vitro models into early drug discovery, Myriamed addresses a critical bottleneck in pharmaceutical R&D—translating preclinical findings to clinical success. The company operates at the intersection of Medical Devices and Digital Health, positioning its technology as a tool for more predictive and efficient drug testing. With applications across multiple therapeutic areas, Myriamed's approach could accelerate the development of novel therapies while minimizing animal testing and improving patient safety. The company's bootstrapped or early-stage status suggests significant upside, though it faces challenges in commercial adoption and scaling. Its success hinges on forming key partnerships with pharmaceutical firms and validating its models against clinical outcomes. As the industry seeks alternatives to traditional preclinical methods, Myriamed is well-positioned to capture a niche in the growing organ-on-a-chip and advanced tissue model market. The team's expertise and the technology's potential to reduce development timelines make it a compelling early-stage investment opportunity.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q2 2027First Major Pharma Partnership50% success
• Q1 2027Publication of Validation Study in Peer-Reviewed Journal70% success